Myelodysplastic Syndromes Diagnosis - Prognosis - Therapy /

This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecula...

Celý popis

Uloženo v:
Podrobná bibliografie
Médium: Elektronický zdroj E-kniha
Jazyk:angličtina
Vydáno: Cham : Springer International Publishing, 2018.
Vydání:1st ed. 2018.
Edice:Hematologic Malignancies,
Témata:
ISBN:9783319768793
ISSN:2197-9766
On-line přístup: Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nam a22000005i 4500
003 SK-BrCVT
005 20220618120956.0
007 cr nn 008mamaa
008 180605s2018 gw | s |||| 0|eng d
020 |a 9783319768793 
024 7 |a 10.1007/978-3-319-76879-3  |2 doi 
035 |a CVTIDW11920 
040 |a Springer-Nature  |b eng  |c CVTISR  |e AACR2 
041 |a eng 
245 1 0 |a Myelodysplastic Syndromes   |h [electronic resource] :  |b Diagnosis - Prognosis - Therapy /  |c edited by Uwe Platzbecker, Pierre Fenaux. 
250 |a 1st ed. 2018. 
260 1 |a Cham :  |b Springer International Publishing,  |c 2018. 
300 |a V, 157 p. 26 illus., 22 illus. in color.  |b online resource. 
490 1 |a Hematologic Malignancies,  |x 2197-9766 
500 |a Medicine  
505 0 |a Diagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. . 
516 |a text file PDF 
520 |a This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection. 
650 0 |a Hematology. 
650 0 |a Oncology . 
856 4 0 |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-76879-3  |y Vzdialený prístup pre registrovaných používateľov 
910 |b ZE09200 
919 |a 978-3-319-76879-3 
974 |a andrea.lebedova  |f Elektronické zdroje 
992 |a SUD 
999 |c 276052  |d 276052